Omeros Stock News

Omeros Corporation (NASDAQ: OMER ) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The response comprises a comprehensive briefing package drafted in close collaboration with external clinical, regulatory, and legal experts addressing the points raised Full story available on Benzinga.com

Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-T

Omeros Corp today responded to an FDA Complete Response Letter received for its Biologics License Application on narsoplimab for a condition that can damage the kidneys.

GWM Advisors LLC raised its holdings in shares of Omeros Co. (NASDAQ:OMER) by 20.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,070 shares of the biopharmaceutical companys stock after purchasing an additional 11,057 shares during the quarter. GWM Advisors LLCs holdings []

Seattle biotech Omeros completed a deal Thursday to sell Omidria, a product used in eye surgery, to Rayner Surgical Group. United Kingdom-based Rayner acquired the Omidria franchise for $126 million. As part of the deal, Omeros is eligible to receive $200 million in commercial milestone payments for the U.S. Food and Drug Administration-approved product, which is used to irrigate eyes during cataract surgery or lens replacement. Together with royalties, the transaction has a value of more than $1 billion, according to a statement. Omidria pulled in $30 million in revenue for Omeros in the third quarter of 2021. This fall, Read More

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that it has completed the sale of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group Inc., an affiliate of Rayner Surgical Group Limited. The transaction was completed pursuant to an Asset Purchase Agreement that was announced on December 2, 2021. Omeros received approximately $126 million in cash at closing. In addition, Omeros retains and is entitled to collect the full amoun

Humanigen (NASDAQ:HGEN) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations. Analyst Recommendations This is a breakdown of recent recommendations and price targets for Humanigen and Omeros, as []

During the last session, Omeros Corporation (NASDAQ:OMER)s traded shares were 1.46 million, with the beta value of the company hitting 0.70. At the end of the trading day, the stocks price was $7.33, reflecting an intraday gain of 3.82% or $0.27. The 52-week high for the OMER share is $23.85, that puts it down -225.38 We Just Learned Something New About Omeros Corporation (NASDAQ: OMER) This Week With Its -3.17% Loss Read More »

Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.

Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.

Wall Street brokerages expect Omeros Co. (NASDAQ:OMER) to announce sales of $94.43 million for the current quarter, Zacks reports. Two analysts have issued estimates for Omeros earnings, with the lowest sales estimate coming in at $31.84 million and the highest estimate coming in at $157.01 million. Omeros posted sales of $10.63 million during the same []

Morgan Stanley increased its stake in shares of Omeros Co. (NASDAQ:OMER) by 23.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 325,154 shares of the biopharmaceutical companys stock after acquiring an additional 60,823 shares during the quarter. Morgan Stanley owned []

Equities research analysts forecast that Omeros Co. (NASDAQ:OMER) will post $31.93 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Omeros earnings. The lowest sales estimate is $31.84 million and the highest is $32.01 million. Omeros reported sales of $10.63 million during the same quarter last year, []

Wall Street analysts predict that Omeros Co. (NASDAQ:OMER) will report ($0.26) earnings per share for the current quarter, Zacks reports. Two analysts have provided estimates for Omeros earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.30). Omeros reported earnings per share of ($0.54) in the same []

Omeros' 2021 was a year to forget with the stock dropping during the year all the way from >$23 to below $6.00.